Phibro Animal Health (Phibro Animal Health) Cash Flow for Dividends : $-19.4 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Phibro Animal Health Cash Flow for Dividends?

Phibro Animal Health's cash flow for dividends for the three months ended in Mar. 2024 was $-4.9 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2024 was $-19.4 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Phibro Animal Health's quarterly payment of dividends increased from Sep. 2023 ($-4.9 Mil) to Dec. 2023 ($-4.9 Mil) but then declined from Dec. 2023 ($-4.9 Mil) to Mar. 2024 ($-4.9 Mil).

Phibro Animal Health's annual payment of dividends increased from Jun. 2021 ($-19.4 Mil) to Jun. 2022 ($-19.4 Mil) but then stayed the same from Jun. 2022 ($-19.4 Mil) to Jun. 2023 ($-19.4 Mil).

Phibro Animal Health Cash Flow for Dividends Historical Data

The historical data trend for Phibro Animal Health's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phibro Animal Health Cash Flow for Dividends Chart

Phibro Animal Health Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash Flow for Dividends

Get a 7-Day Free Trial

-18.59

-19.42

-19.43

-19.44

Phibro Animal Health Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash Flow for Dividends	Get a 7-Day Free Trial															-4.86	-4.86	-4.86	-4.86	-4.86

Phibro Animal Health Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.4 Mil.

Phibro Animal Health Cash Flow for Dividends Related Terms

Thank you for viewing the detailed overview of Phibro Animal Health's Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.

Phibro Animal Health (Phibro Animal Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Phibro Animal Health Corp (NAS:PAHC) » Definitions » Cash Flow for Dividends

Comparable Companies

Traded in Other Exchanges

PB8:Germany

Address

300 Frank W. Burr Boulevard, Suite 21, 3rd Floor, Glenpointe Centre East, Teaneck, NJ, USA, 07666-6712

Website

https://www.pahc.com

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

Executives

Judith Weinstein	officer: See Remarks	C/O PHIBRO ANIMAL HEALTH CORP, 300 FRANK W. BURR BOULEVARD, STE 21, TEANECK NJ 07666
Alejandro Bernal	director	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
E Thomas Corcoran	director
Larry Lee Miller	officer: Chief Operating Officer	8 HAZELWOOD COURT, WARREN NJ 07059
Damian Finio	officer: Chief Financial Officer	C/O IGI LABORATORIES, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Robin Aukerman	officer: President,North America Region	C/O PHIBRO, GLENPOINTE CENTRE EAST, 3RD FL, 300 FRANK W. BURR BLVD, STE 21, TEANECK NJ 07666
Daniel M Bendheim	director, officer: Exec. VP, Corporate Strategy	300 FRANK W. BURR BOULEVARD, SUITE 21, TEANECK NJ 07666
Dean J Warras	officer: Pres Animal Health & Nutr N.A.	5113 SPYGLASS HILL, QUINCY IL 62305
Jack Bendheim	director, 10 percent owner, officer: President and CEO	C/O EMPIRE RESOURCES, INC., 1 PARKER PLAZA, SUIET 10, FORT LEE NJ 07024
Bfi Co., Llc	10 percent owner	300 FRANK W. BURR BLVD., STE 21, TEANECK NJ 07666
Jonathan Bendheim	director	GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ 07666
Anthony Andolino	officer: SEE REMARKS	GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD., STE 21, TEANECK NJ 07666
Richard G Johnson	officer: Chief Financial Officer	7 WEST 96TH STREET, APT. 11C, NEW YORK NY 10025
Gerald K Carlson	director	2496 OLD BEACH ROAD, WAYZATA MN 55391
Thomas G Dagger	officer: SVP, Gen Counsel and Corp Sec	41 WILCOX DRIVE, MOUNTAIN LAKES NJ 07046